News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Hyperion Therapeutics to Report Results of HALT-HE Study at American Association for Study of Liver Diseases Plenary Session



10/3/2012 9:52:00 AM

SOUTH SAN FRANCISCO, Calif., Oct. 2, 2012 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) announced today that the results of the HALT-HE Study will be presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) (The Liver MeetingĀ®), taking place on November 9-13, 2012 in Boston, MA. The presentation, "Randomized, controlled, double-blind study of glycerol phenylbutyrate in patients with cirrhosis and episodic hepatic encephalopathy," will be made on Monday, November 12, 2012, at 8:45 a.m. ET in the Presidential Plenary Session I in the Hynes Convention Center Auditorium.

Read at GlobeNewswire

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES